Drug intelligence / Profile preview

autologous murine BCMA-CAR T cells

Development stage: Unknown
Lead developer: Shanghai YaKe Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Autologous murine BCMA-CAR T cells (also known as YK-BCMA BB-002) is a second-generation chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA/CD269). Developed by Shanghai YaKe Biotechnology in collaboration with Beijing Boren Hospital, the therapy utilizes autologous T cells transduced with a lentiviral vector encoding a murine-derived single-chain variable fragment (scFv) specific for BCMA, along with a 4-1BB costimulatory domain and a CD3ζ signaling domain. It is primarily being evaluated in clinical trials for the treatment of relapsed or refractory multiple myeloma (RRMM) and secondary plasma cell leukemia (sPCL).

Other names: autologous murine anti-BCMA CAR-T cellsmurine anti-BCMA-CD3ζ-4-1BB CAR-T cells

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on autologous murine BCMA-CAR T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous murine BCMA-CAR T cells.

Explore the full profile